Notice of Preliminary Results

RNS Number : 1868M

Avacta Group PLC

13 September 2012

 



Press release

13 September 2012

Avacta Group plc

("Avacta" or "the Group")

Notice of Preliminary Results

Avacta Group plc (AIM:AVCT), a leading healthcare technology, reagents and consumables company providing proprietary analytical and diagnostics solutions to the life sciences/healthcare sector, has brought forward the announcement of its Preliminary Results for the year ended 31 July 2012, to 23 October 2012. The Group previously noted within its pre-close trading update, issued on 24 August 2012, that the Preliminary Results were expected to be announced on 30 October 2012.

An analyst briefing given by Alastair Smith, Chief Executive Officer and Tim Sykes, Chief Financial Officer will be held at 10:30hrs, on 23 October 2012, at Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.

-Ends-

For further information please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer	Tel: [phone]  www.avacta.com
Panmure Gordon (UK) Limited.      Andrew Burnett/ Fred Walsh Charles Leigh-Pemberton/Grishma Patel	Tel:  [phone] www.panmure.com
Media Enquiries Abchurch Communications Sarah Hollins / Adam Michael / Harriet Rae [e-mail]	Tel: [phone] www.abchurch-group.com

Notes to Editors:

Avacta Group plc, is a UK based healthcare technology, reagents and consumables company, providing innovative tools to help reduce the costs of drug development and to improve diagnostics.

Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.

The cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.

Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

For further information visit www.avacta.com

 

END

 

 

NORKXLBFLKFLBBL